Home Photos Surgery Types Cosmetic Surgeons Surgery Prices Surgery Risks Plastic Surgery News

Panel rejects Sanofi obesity drug (Reuters)

A worker handles vials of medicine in a laboratory of pharmaceutical company Sanofi-Aventis in Ambares, France, September 20, 2006. U.S. regulators should reject a proposed Sanofi-Aventis weight-loss pill called Zimulti because of concerns it may increase suicidal thinking and depression, an advisory panel unanimously said on Wednesday. (Regis Duvignau/Reuters)Reuters - U.S. regulators should reject a proposed weight-loss pill called Zimulti because of concerns it may increase suicidal thinking and depression, an advisory panel unanimously said on Wednesday.


More: continued here





You can respond, or trackback from your own site.


Related News

  • Panel rejects new weight-loss drug (AP)
  • Sanofi obesity drug faces tough EU safety review (Reuters)
  • Key US drug panel rejects Sanofi's obesity pill (AFP)
  • Merck obesity drug shows weight loss in study (Reuters)
  • Obesity drug has little effect on heart in teens (Reuters)
  • Sanofi pulls obesity drug application in U.S. (Reuters)
  • Lancet, BMJ studies sound concern over anti-obesity drug rimonabant (AFP)
  • The Weight of the World (Cavalier Daily Online)
  • Death risks high after weight loss surgery: study (Reuters)
  • Weight Loss Surgery Expert Dr. Stephen J. McColgan Joins DAL International's Medical Advisory Board (Marketwire via Yahoo! Finance)


    • Leave a Reply
    Cosmetic Surgery Procedure.com | Cosmetic Surgery Types | Find a Cosmetic Surgeon | Cosmetic Surgery Prices | Cosmetic Surgery Risks | Resources | Contact Us